Attached files

file filename
EX-32.2 - EX-32.2 - BIOLASE, INCbiol-ex322_132.htm
EX-32.1 - EX-32.1 - BIOLASE, INCbiol-ex321_11.htm
EX-31.2 - EX-31.2 - BIOLASE, INCbiol-ex312_131.htm
EX-31.1 - EX-31.1 - BIOLASE, INCbiol-ex311_13.htm
EX-21.1 - EX-21.1 - BIOLASE, INCbiol-ex211_7.htm
EX-10.29 - EX-10.29 - BIOLASE, INCbiol-ex1029_554.htm
EX-10.28 - EX-10.28 - BIOLASE, INCbiol-ex1028_553.htm
EX-10.27 - EX-10.27 - BIOLASE, INCbiol-ex1027_552.htm
EX-10.26 - EX-10.26 - BIOLASE, INCbiol-ex1026_499.htm
EX-4.4 - EX-4.4 - BIOLASE, INCbiol-ex44_500.htm
10-K - 10-K - BIOLASE, INCbiol-10k_20171231.htm

 

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

BIOLASE, Inc.

Irvine, California

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-194889, 333-144095, 333-112173, 333-130677, 333-177339, 333-204059, and 333-150105) and Form S-3 (Nos. 333-222564, 333-219406, 333-106260, 333-200623, 333-198291, 333-166145, 333-190158, 333-193426, 333-214281, 333-175664, 333-141417, 333-106260, 333-106290, 333-89692, and 333-58329) of BIOLASE, Inc. of our report dated March 14, 2018, relating to the consolidated financial statements and consolidated financial statement schedule of BIOLASE, Inc., which appear in this Form 10-K.  Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.  

/s/ BDO USA, LLP

Costa Mesa, California

March 14, 2018